Determining the appropriate retatrutide amount is critically essential for obtaining optimal benefits. Initially, patients typically begin with a low amount of approximately 2.4 mg, given every week via subcutaneous . This preliminary dose is then gradually raised every four periods, up to a maximum amount of 10.8 mg, depending on person response